Head-to-head comparison
| Property | CJC-1295 | Tesamorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Reclassification Pending | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~30 minutes (no DAC) / ~8 days (with DAC) | ~26-38 minutes |
| Mol. Weight | 3,367.97 Da | 5,135.89 Da |
| Side Effects | Flushing, Headache, Dizziness | Injection site reactions (pain, redness), Joint pain, Nausea |
Key differences
- FDA status: Tesamorelin is FDA-approved (Egrifta SV); CJC-1295 has never been FDA-approved and remains a research compound.
- Dosing frequency: CJC-1295 with DAC is dosed 1–2 times weekly; tesamorelin is dosed daily. This is CJC-1295's primary practical advantage.
- Half-life: CJC-1295 with DAC has a half-life of 6–8 days; tesamorelin has a much shorter half-life requiring daily injection.
- Clinical evidence: Tesamorelin has Phase III trial data demonstrating approximately 18% trunk fat reduction; CJC-1295 has limited published clinical data.
- GH release pattern: CJC-1295 with DAC produces sustained baseline GH elevation; tesamorelin produces daily pulsatile GH spikes that are considered more physiological.
- Variants: CJC-1295 comes in two forms — with DAC (long-acting) and without DAC (Mod GRF 1-29, short-acting); tesamorelin has one form.
- Availability: CJC-1295 is available from research suppliers; tesamorelin requires a prescription.
The verdict
Tesamorelin wins on evidence quality with FDA approval and published clinical efficacy data for fat reduction. CJC-1295 with DAC wins on dosing convenience (weekly vs daily) but lacks comparable clinical evidence. For evidence-based practice, tesamorelin is the supported choice. For research protocols where weekly dosing is prioritized and clinical-grade evidence is not required, CJC-1295 with DAC is the practical alternative.
Frequently asked questions
CJC-1295 has limited published clinical data compared to tesamorelin's Phase III trials. Both stimulate GH release through the GHRH pathway, but tesamorelin has demonstrated approximately 18% visceral fat reduction in controlled trials. CJC-1295's efficacy is primarily supported by preclinical data and community reports.
CJC-1295 with DAC (Drug Affinity Complex) has a dramatically extended half-life of 6–8 days due to albumin binding, enabling weekly dosing. Tesamorelin has a shorter half-life without this modification. CJC-1295 without DAC (Mod GRF 1-29) has a short half-life similar to tesamorelin.
Both act on the GHRH receptor, so combining them would be redundant. Choosing one GHRH analog and optionally adding a ghrelin-pathway peptide (like ipamorelin) provides complementary synergy through different receptor systems.
Tesamorelin has a more characterized safety profile from clinical trials. CJC-1295 with DAC may cause injection site reactions and transient flushing. Both can cause water retention and joint pain associated with GH elevation. Tesamorelin's FDA approval provides greater safety data confidence.
Tesamorelin has direct clinical evidence for visceral fat reduction. CJC-1295 stimulates GH through the same pathway but lacks comparable published fat loss data. For evidence-based fat reduction specifically, tesamorelin is the stronger option.